Literature DB >> 8766893

[Effect of low dose omega-3 fatty acid supplementation on plasma lipids and lipoproteins in coronary patients with dyslipoproteinemia].

O S Schindler1, R Rost.   

Abstract

In a prospective study, 20 patients (aged 48-67 years) with primary hyperlipoproteinaemia of phenotypes IIa, IIb, IV and with proven coronary sclerosis received four different doses of long-chain polyunsaturated omega-3 fatty acids. 0.18 to 1.1 g per day were administered in the form of fish oil capsules over four 2-week periods. The aim was to study the effect of different low dose supplementations of n-3 fatty acids on the plasmalipid- and lipoprotein composition and to determine a threshold of effectiveness. Significant reduction of the triglyceride level was registered in all subjects with the greatest decrease in those patients who presented with the highest base levels. The cholesterol and LDL-cholesterol values on average remained almost unchanged, apart from a significant increase of LDL-cholesterol in patients with type IV hyperlipoproteinaemia. The HDL-cholesterol fraction also showed a significant increase in type IIb patients which was related to alterations of the HDL-3 subfraction. The minimal effective dose of a daily administration of omega-3 fatty acids can be expected between 0.18 g and 0.35 g. The observed changes of plasmalipids and lipoproteins reflect the beneficial effect of long-chain polyunsaturated omega-3 fatty acids in respect to plasma-triglyceride reduction and HDL-cholesterol increase as seen in other studies, despite the use of supplementations far below 1 g per day.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8766893     DOI: 10.1007/bf01622869

Source DB:  PubMed          Journal:  Z Ernahrungswiss        ISSN: 0044-264X


  39 in total

1.  A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA.

Authors:  D S FREDRICKSON; R S LEES
Journal:  Circulation       Date:  1965-03       Impact factor: 29.690

Review 2.  [Epidemiologic and biochemical studies of n-3 fatty acids in the prevention of atherosclerosis].

Authors:  P C Weber
Journal:  Internist (Berl)       Date:  1989-05       Impact factor: 0.743

3.  Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil.

Authors:  D R Sullivan; T A Sanders; I M Trayner; G R Thompson
Journal:  Atherosclerosis       Date:  1986-08       Impact factor: 5.162

Review 4.  Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review.

Authors:  W S Harris
Journal:  J Lipid Res       Date:  1989-06       Impact factor: 5.922

5.  Long-term effect of mackerel diet on blood pressure, serum lipids and thromboxane formation in patients with mild essential hypertension.

Authors:  P Singer; I Berger; K Lück; C Taube; E Naumann; W Gödicke
Journal:  Atherosclerosis       Date:  1986-12       Impact factor: 5.162

6.  Plasma lipoproteins and fatty acid composition during a moderate eicosapentaenoic acid diet.

Authors:  M Thorngren; E Nilsson; A Gustafson
Journal:  Acta Med Scand       Date:  1986

7.  Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients.

Authors:  P V Subbaiah; M H Davidson; M C Ritter; W Buchanan; J D Bagdade
Journal:  Atherosclerosis       Date:  1989-10       Impact factor: 5.162

Review 8.  Fish oil consumption and decreased risk of cardiovascular disease: a comparison of findings from animal and human feeding trials.

Authors:  P M Herold; J E Kinsella
Journal:  Am J Clin Nutr       Date:  1986-04       Impact factor: 7.045

9.  Fish oils in hypertriglyceridemia: a dose-response study.

Authors:  W S Harris; D W Rothrock; A Fanning; S B Inkeles; S H Goodnight; D R Illingworth; W E Connor
Journal:  Am J Clin Nutr       Date:  1990-03       Impact factor: 7.045

10.  Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia.

Authors:  T A Sanders; D R Sullivan; J Reeve; G R Thompson
Journal:  Arteriosclerosis       Date:  1985 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.